Immunotherapy re-treatment for veterans with lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether restarting immunotherapy along with chemotherapy and radiation can help veterans with stage III lung cancer that cannot be removed by surgery. It's for people whose tumors have a certain protein (PD-L1) and who haven't had these treatments before for advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are physically active enough to do daily activities (ECOG score 0 or 1).
- Your lung cancer is stage III and cannot be removed surgically.
- Your tumor tests positive for a protein called PD-L1 (at least 1%).
- You have not had radiation to the chest or chemotherapy for advanced lung cancer before.
- You do not have an autoimmune disease needing strong immune-suppressing drugs, active tuberculosis, hepatitis B or C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving radiation and immunotherapy together to people with advanced lung cancer that hasn't been treated yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests an investigational microbiome therapy (EXL01) combined with nivolumab (an immunotherapy) for people with advanced non-small cell lung cancer whose cancer continued to grow after standard immunotherapy and chemotherapy. The goal is to see if adding EXL01 can help the immune system fight the cancer again.
This trial tests whether adding a NAD+ booster (NMN) to radiation and immunotherapy can help people with advanced lung cancer. It may improve the effectiveness of the treatment and help you live longer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.